|
    ACAD U.S.: Nasdaq

    ACADIA Pharmaceuticals Inc.

    ACADUS
    After Hours
    Back To Top
    Last Updated: Jul 26, 2021 6:13 p.m. EDT Delayed quote

    $ 21.30

    0.01 0.05%
    After Hours Volume: 18.85K
    Close Chg Chg %
    $21.29 -0.17 -0.79%
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 1.63M 65 Day Avg: 1.74M
    93% vs Avg
    20.90 Day Range 21.90
    19.20 52 Week Range 57.46

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ACAD Overview

    Performance

    5 Day
    • -8.27%
    1 Month
    • -15.95%
    3 Month
    • -0.28%
    YTD
    • -60.18%
    1 Year
    • -51.97%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 21 Full Ratings

    Recent News

    • eLesor
    • Dow Jones
    Read full story

    5 Undervalued Healthcare Stocks

    Read full story

    Travere Therapeutics’ Disappointment Is Another Sign of a Tougher FDA

    Read full story

    Will Biotech Stocks’ Slide Become a Rout? June Holds the Key.

    Acadia Pharmaceuticals stock price target cut to $26 from $40 at Canaccord Genuity

    Acadia Pharmaceuticals downgraded to hold at Canaccord Genuity

    Read full story

    Acadia Is Hit by Wave of Downgrades After FDA Rejection

    Acadia Pharmaceuticals stock price target cut to $25 from $37 at Mizuho

    Acadia Pharmaceuticals downgraded to neutral from buy at Mizuho

    Read full story

    Acadia Stock Is Plunging Again. The FDA Rejected a Drug Application.

    Read full story

    The FDA Is Clamping Down. What That Means for Biotech Stocks.

    Acadia Pharmaceuticals stock price target cut to $37 from $55 at Mizuho

    Acadia Pharmaceuticals stock price target cut to $40 from $61 at Canaccord Genuity

    Acadia Pharmaceuticals stock leads premarket losers after FDA finds undisclosed 'deficiencies' in NDA

    Read full story

    Acadia Shares Plummet After FDA Finds Flaws in Drug Application

    Acadia Pharmaceuticals downgraded to outperform from strong buy at Raymond James

    Acadia Pharmaceuticals stock price target cut to $42 from $60 at J.P. Morgan

    Acadia Pharmaceuticals stock price target cut to $27 from $68 at Stifel Nicolaus

    Acadia Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus

    Acadia Pharmaceuticals stock price target cut to $55 from $70 at Mizuho

    Read full story

    Premarket Movers: ACADIA Pharmaceuticals, Stitch Fix Cl A, GameStop Cl A

    • Other News
    • Press Releases

    Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

    on Zacks.com

    Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

    on Zacks.com

    AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe

    on Zacks.com

    Bear of the Day: Inovio Pharmaceuticals (INO)

    on Zacks.com

    ACADIA Pharmaceuticals (ACAD) Initiated with a Hold at Berenberg Bank

    on SmarterAnalyst

    Why Is Acadia (ACAD) Up 11.3% Since Last Earnings Report?

    on Zacks.com

    Here's How Much You'd Have If You Invested $1000 in Acadia Pharmaceuticals a Decade Ago

    on Zacks.com

    Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Catalyst Pharma (CPRX) and Minerva Neurosciences (NERV)

    on SmarterAnalyst

    Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), Inotiv (NOTV) and NuVasive (NUVA)

    on SmarterAnalyst

    Analysts’ Top Healthcare Picks: ACADIA Pharmaceuticals (ACAD), Lumos Pharma (LUMO)

    on SmarterAnalyst

    ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates

    on Zacks.com

    Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Bruker (BRKR) and Rigel (RIGL)

    on SmarterAnalyst

    Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD) and Bluebird Bio (BLUE)

    on SmarterAnalyst

    Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates

    on Zacks.com

    ACADIA Pharmaceuticals (ACAD) Receives a Hold from Oppenheimer

    on SmarterAnalyst

    Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    on Zacks.com

    Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

    on Zacks.com

    Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

    on Zacks.com

    Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Atara Biotherapeutics (ATRA) and FibroGen (FGEN)

    on SmarterAnalyst

    Is Acadia a Buy Following the FDA’s CRL? J.P. Morgan Says ‘Yes’

    on TipRanks.com

    ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

    Competitors

    Name Chg % Market Cap
    Eli Lilly & Co. -0.39% $234.15B
    Vanda Pharmaceuticals Inc. -0.10% $1.09B
    Johnson & Johnson 0.05% $452.39B
    Bristol Myers Squibb Co. -0.95% $152.67B
    Pfizer Inc. 0.31% $233.31B
    Adamas Pharmaceuticals Inc. -2.63% $224.32M
    Catalyst Biosciences Inc. -1.86% $135.12M
    Competitor Data Provided ByCapital Cube Logo